Facebook and TLabs accelerator have partnered to strengthen the mobile startup ecosystem in India. Both Facebook and TLabs have a strong focus and expertise on Internet and Mobile businesses, and will build on the knowledge and learnings of in-house senior mentors to engage and educate budding entrepreneurs. As part of this partnership, they will co-host multiple events for solving startups’ issues around user experience, analytics, app installs, monetization and more.

TLabs is a startup accelerator and early-stage seed fund for internet and mobile technology startups in India.

Facebook will also provide FbStart referral codes to TLabs for use by TLabs’s mobile portfolio companies. FbStart is a global program designed to help mobile startups build and grow their apps. Startups with a live mobile app on Google Play/iOS stores or a working Messenger bot can apply for the FbStart Program and membership is awarded to selected start-ups, post a review from the Facebook team.

These startups will receive ad credits from Facebook and benefits from more than 30 partners, including AWS, Dropbox, SalesForce and MailChimp. Along with these benefits, startups in the FbStart program will also get support and mentorship from Facebook’s product experts and join an exclusive community of global start-ups.

TLabs COO, Abhishek Gupta said, “It’s an incredible step by Facebook for the mobile ecosystem, and start-ups would be highly benefited from being a part of the Facebook global community.”

Satyajeet Singh, Head - Product Partnerships, Facebook India, commented that partnering with TLabs was a progressive decision towards creating an empowered start-up ecosystem in the country.

Notably, with 50+ companies, 7 Exits, $200M+ market cap of the portfolio and connecting to over 200 Angels and most VCs India and abroad, TLabs has seen a tremendous success rate with over 65% of the companies getting funded after graduation raising over $450k investments per team.
Advertisements

Post a Comment

Previous Post Next Post
Like this content? Sign up for our daily newsletter to get latest updates.